Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
IVERIC bio, Inc.
Participants were randomized in a 1:1 ratio to the following monthly treatment groups:
* Avacincaptad pegol 2 mg
* Sham
At Month 12, the participants in the avacincaptad pegol 2mg treatment group were re-randomized to receive the study drug either on a monthly basis or on an every other month basis
The participants initially randomized to sham treatment continued with monthly sham administration through Month 23
All participants had a final follow up visit at Month 24
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects of either gender aged ≥ 50 years
Diagnosis of Non-foveal GA secondary to dry AMD
You may not be if
Any prior treatment for AMD (dry or wet) or any prior intravitreal treatment for any indication in either eye, except oral supplements of vitamins and minerals
Any intraocular surgery or thermal laser within 3 months of trial entry.
Any prior thermal laser in the macular region, regardless of indication
Any ocular or periocular infection (including blepharitis), or ocular surface inflammation in the past 12 weeks.
Previous therapeutic radiation in the region of the study eye
Any sign of diabetic retinopathy in either eye
Clareo Health | A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)
